Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04049331 · ClinicalTrials.gov registry record · Phase 2
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
A Phase 2 study of Hypogonadism, Male and Fatigue Syndrome, Chronic, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 2
- Study locations
NCT04049331 is a Phase 2 study of Hypogonadism, Male and Fatigue Syndrome, Chronic that is actively recruiting participants, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 240 participants, above the 92-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (161% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT04049331, a Phase 2 study of Hypogonadism, Male and Fatigue Syndrome, Chronic, is actively recruiting participants, sponsored by Seattle Institute for Biomedical and Clinical Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
Washington
- Veterans Affairs Puget Sound Health Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04049331
The ClinicalTrials.gov registry entry for NCT04049331 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (161% higher). The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypogonadism, Male appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT04049331 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT04049331 about?
NCT04049331 is a clinical study titled "Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone". The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who...
What is the current status of trial NCT04049331?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2021-03-22. Estimated completion is 2027-01-30.
What conditions does trial NCT04049331 study?
This clinical trial studies the following conditions: Hypogonadism, Male, Fatigue Syndrome, Chronic.
What interventions are being tested in trial NCT04049331?
The interventions under investigation include: placebo (OTHER), Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED] (DRUG).
Who is sponsoring clinical trial NCT04049331?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04049331 being conducted?
This trial has 2 study locations across Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
-
Clomid in Men With Low Testosterone With and Without Prior Treatment
COMPLETED · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.